Orogenital transmission is often suspected but rarely proven (1). In our study, use of whole-genome sequencing strongly supported the hypothesis that the oropharyngeal carriage of *N. meningitidis* by the man who performed oral sex was the source of the urethritis. Moreover, whole-genome sequencing showed that the strains belonged to the ST11 clonal complex. Several studies reported nongonococcal urethritis caused by *N. meningitidis* ST11 in Japan and the United States (1,6,7). These worldwide descriptions suggest that *N. meningitidis* S11 might represent an emerging urethrotropic clade.

This case is notable because the patient had highly symptomatic urethritis without risky sexual behavior. In fact, he reported that he and his only sexual partner had not had sex with others before they met.

Since 2010, several clusters of serogroup C invasive meningococcal disease have been reported among men who have sex with men, and sexual transmission is suspected to be involved (8–10). These infections led to an extension of the meningococcal vaccine recommendations to men who have sex with men who are engaged in risky behavior in some outbreaks areas. Our case highlights that sexual transmission of *N. meningitidis* should be considered for all men.

Finally, although systematically collected information is limited, meningococcal urogenital infections are potentially increasing and raising public health concerns. These infections need to be monitored, and bacteriological culture of purulent exudate should always be considered when available. Also, because fidelity might be contested between partners when a sexually transmitted disease is being diagnosed, identification of meningococcal urethritis and its transmission might have a strong psychological effect on the couple.

**About the Author**

Dr. Jannic is an attending physician at the Service de Dermatologie, Hôpital Bichat Claude Bernard, Paris, France. His research interests include dermatologic infectious diseases.

**References**


**Address for correspondence:** Arnaud Jannic, Hôpital Bichat Claude Bernard, 46 Rue Henri Huchard, 75018 Paris, France; email: arnaud.jannic@aphp.fr

**Trends in Azole Resistance in Aspergillus fumigatus, the Netherlands, 1994–2016**

**Jochem B. Buil, Eveline Sneelder, Laura Bedin Denardi, Willem J.G. Melchers, Paul E. Verweij**

Author affiliations: Radboud University Medical Center, Nijmegen, The Netherlands (J.B. Buil, W.J.G. Melchers, P.E. Verweij); Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen (J.B. Buil, W.J.G. Melchers, P.E. Verweij); Wageningen University and Research, Wageningen, the Netherlands (E. Sneelder); Federal University of Santa Maria, UFSM, Santa Maria, Brazil (L.B. Denardi)

DOI: https://doi.org/10.3201/eid2501.171925
We investigated azole resistance in *Aspergillus fumigatus* in a tertiary reference hospital in the Netherlands during 1994–2016. The 5-year patient-adjusted proportion of resistance increased from 0.79% for 1996–2001 to 4.25% for 2002–2006, 7.17% for 2007–2011, and 7.04% for 2012–2016. However, we observed substantial variation between years.

Azole resistance is increasingly reported in *Aspergillus fumigatus* and is now found all around the world (1). Most studies have investigated the presence of resistance in environmental or clinical samples over a limited time, but longitudinal resistance studies are lacking. It is important to determine if azole resistance frequency shows increasing trends over time and if the distribution of resistance mutations changes over time. We have previously reported the emergence of azole resistance from 1994–2007 for the Radboud University Medical Center (RUMC) in Nijmegen, the Netherlands (2). Here, we describe trends in resistance frequency and distributions of mutations over a 23-year period, from 1994 through 2016.

All clinical *A. fumigatus* isolates cultured at RUMC are screened for azole resistance. Before 2009, isolates were screened using an agar-slant supplemented with 4 mg/L itraconazole (2). During 2009–2011 a 4-well plate was developed containing itraconazole (4 mg/L), voriconazole (1 mg/L), posaconazole (0.5 mg/L), and a growth control. Since 2012, we have used a commercial agar-based screening system (VIPcheck, http://www.vipcheck.nl) containing 2 mg/L of voriconazole (3,4). We performed EUCAST susceptibility testing (http://www.eucast.org) and sequencing of the *cyp51A* gene and promoter on isolates that grew on azole-containing wells (2).

We calculated the resistance frequency of azole-resistant *A. fumigatus* isolates for each year, using the number of cultured isolates as denominator. Furthermore, we calculated the patient-adjusted proportion of resistance for each year and for each 5-year period, using the number of patients with a resistant isolate as numerator and of culture-positive patients as denominator. We determined by χ² test whether trends of resistance frequency were statistically significant (p<0.05). When 2 different resistance mechanisms were recovered from a single patient, we counted the patient once for determining the resistance proportion but used both isolates to determine the resistance frequency.

Over the 23-year period, 4,268 *A. fumigatus* isolates were cultured from 2,051 patients, a resistance frequency of 4.2% (179/4,268 isolates). Azole-resistant *A. fumigatus* was found in 109/2,051 (5.3%) culture-positive patients (Figure, panel A). The patient-adjusted resistance proportion increased from 0% in 1997 to 9.5% in 2016 (Figure, panel B). The increase of resistance was not statistically significant when the proportion of resistance for each consecutive year was analyzed. However, the 5-year proportion of resistance increased from 0.79% for 1996–2001 to 4.25% for 2002–2006, 7.17% for 2007–2011, and 7.04% for 2012–2016 (Figure, panel A). The increases in resistance for 2002–2006 compared with 1996–2001 and for 2007–2011 compared with 2002–2006 were statistically significant (p<0.05) (Figure, panel B).

**TR34/L98H** was the most prevalent resistance mutation over the 23-year period; it was present in 77/109 (70.6%) patients with drug-resistant *A. fumigatus* (Figure, panel C). **TR46/Y121F/T289A** was found in 2 patients in 2010, 1 in 2011, and 1 in 2012 but only twice during 2013–2016. In recent years, resistant phenotypes without *Cyp51A* mutations were encountered more frequently than phenotypes with the mutation (Figure 1, panel C).
We observed an increasing trend in azole resistance prevalence in clinical *A. fumigatus* isolates until 2011, using number of patients with a positive culture as denominator. After 2011, the 5-year proportion of resistance remained stable. The advantages and disadvantages of different approaches of reporting resistance frequency remain under debate (5). Experts have recommended 10% resistance rate as the threshold for reconsideration of primary antifungal therapy (6), which indicates a need for consensus in how to determine resistance rates (5).

Although we found a substantial increase in azole resistance frequency over time, our study showed variation between consecutive years. Therefore, analysis of culture-positive patients over multiple years is required to determine local resistance epidemiology. Furthermore, resistance rates calculated using *Aspergillus* disease as denominator provide more information to support changes in empiric treatment decisions, but the low number of culture-positive patients in risk groups makes it difficult to obtain accurate estimates.

Various factors might have caused bias over the long period. The method of resistance detection changed from an agar-slab containing itraconazole to a system that contained 3 azoles. Voriconazole- or posaconazole-resistant isolates with low itraconazole MICs may have been initially missed, but this phenotype is very uncommon (7). Other factors include increased awareness of resistance, the policy to screen multiple *A. fumigatus* colonies after observation of patients with mixed azole-susceptible and azole-resistant infection (8), and local changes in aspergillosis disease risk groups.

Resistance was dominated by environmental resistance mutations TR46/Y121F and TR34/L98H, although the number of patients with TR34/L98H decreased in recent years. Furthermore, in the last 5 years, ≥15% of resistant isolates harbored a wild-type *Cyp51A* gene, suggesting that other resistance mechanisms may be emerging. Because commercial PCR tests detect only resistance mechanisms with TR46/Y121F and TR34/L98H, our observation is relevant for using these assays in culture-negative patients.

In summary, our study indicates an increasing azole resistance trend in clinical *A. fumigatus* isolates in the Netherlands. Furthermore, our results highlight difficulties encountered in establishing local epidemiology of this resistance.

This study was supported by internal funding.

Disclosures: P.E.V. has received research grants from Gilead Sciences, Astellas, Merck Sharp & Dohme (MSD), F2G, and BioRad, is a speaker for Gilead Sciences and MSD, and is on the advisory boards for Pfizer, MSD, and F2G. All other authors have nothing to declare.

**About the Author**

Dr. Buil is currently a resident in clinical microbiology and PhD student at Radboud University Medical Center in Nijmegen, the Netherlands. His research interests include the diagnosis of azole-resistant aspergillosis and preclinical studies of new antifungal agents.

**References**


Address for correspondence: Jochem B. Buil, Department of Medical Microbiology, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, the Netherlands; email: jochem.buil@radboudumc.nl